cas 913581-92-7|| where to buy 6,7-Dihydrothieno[3,2-d]pyrimidine-2,4-diol

Nom du produit:6,7-Dihydrothieno[3,2-d]pyrimidine-2,4-diol

IUPAC Name:6H,7H-thieno[3,2-d]pyrimidine-2,4-diol

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM151516-1g	1-2 Weeks	ƿƛȡ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 913581-92-7 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:913581-92-7; Formule moléculaire:C6H6N2O2S; Point de fusion:-; Code SMILES:OC1=NC(O)=C2SCCC2=N1; Densité:

: Numéro de catalogue:CM151516; Poids moléculaire:170.19; Point d'ébullition:; N° Mdl:; Stockage:Store at 2-8°C.

: Thienopyrimidines; Thienopyrimidines are a class of heterocyclic compounds with diverse biological activities depending on their detailed substitution patterns. In addition, many thienopyrimidine derivatives have shown potent activity against cancer cell lines and specific oncogenes.

: Nerandomilast; Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study.
Nerandomilast (BI 1015550) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). This compound is an investigational agent and has not been approved for use. Nerandomilast was granted FDA Breakthrough Therapy Designation for the treatment of IPF in February 2022.